Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology?
In the United States, the passage of the Bayh-Dole Act in 1980 encouraged universities to license inventions for commercial development. Although this financial incentive can stimulate academic researchers to discover new drugs and devices, there is concern that the possibility of monetary reward could distort investigators' objectivity.
McKinney
Ross
R
Duke University School of Medicine, Durham, North Carolina, USA. ross.mckinney@duke.edu
Korn
David
D
D035843:Biomedical Research / Q000191:economics*; D002986:Clinical Trials as Topic; D016265:Conflict of Interest; D004864:Equipment and Supplies; D008004:Licensure; D011640:Public Policy; D014481:United States